Date



|Date : |2007 |09 |13 |

Note for attention: further details on the Partner Profile Form (PPF) can be found in the Topic PPF_FP7_T1.8 (page 4/4).

|PPF_FP7_T1.1 Details of the organization and of the main researcher |

|Contact person details |

|Name, Title |Manuel José Lopes (PhD) |Gender (M/F): |M |

|Tel.: |+351 266 730 300 |Fax. |+351 266 730 350 |E-mail: |mjl@uevora.pt |

|Personnel website: | |

|Organization/research Group details |

|Name: |Centro de Investigação em Ciências e Tecnologias da Saúde (CIC&TS) |

|Street name and number: |Escola Superior de Enfermagem S. João de Deus, Universidade de Évora |

| |Largo Sr. da Pobreza, 7000-811 Évora PORTUGAL |

|City, Postal address: |Évora |P.O Box |7000-811 |Country |Portugal |

|Website | |

| Organization activity type[1] | HES | IND | REC | N/A | OTH _______________ |

|Organization legal status type | Public Private Non-profit OTH _______________ |

|PPF_FP7_T1.2 Personal profile and work history of the research group/organization |

|(brief description - max 12 lines) |

| |

|CIC&TS has as main objective to investigate the relevant health problems occurring at any stage of the human life cycle, emphasizing |

|specifically those occurring in elderly people. This goal will be achieved through the development of research programs, establishment of |

|clinical orientated standards, orienting upgraded studies in Community Health and Services and other activities promoting and enhancing |

|knowledge about ageing and its health problems and consequently about quality of life. CIC&TS is organized in 2 research teams: |

| |

|Health and Disease Process and Practice of Health Care for Elderly and Families |

|Experimental Biomechanics, Physical Activities, Well Being and Rehabilitation |

|PPF_FP7_T1.3 Areas of expertise and interest of the Research Group [activities and areas under the 2007 Work Programme for the Health Theme: Calls |

|FP7-HEALTH-2007-A (2007A) & FP7-HEALTH-2007-B (2007B)] |

|Activity / Area |2007-A |2007-B |

|1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH |√ |√ |

| |1.1. High-throughput research |√ |√ |

| |1.2. Detection, diagnosis and monitoring |√ |√ |

| |1.3. Predicting suitability, safety and efficacy of therapies |√ |- |

| |1.4. Innovative therapeutic approaches and interventions |√ |√ |

|2. TRANSLATING RESEARCH FOR HUMAN HEALTH |√ | |

| |2.1. Integrating biological data and processes: Large-scale data gathering, systems biology |√ |√ |

| | |2.1.1. Large scale data gathering |√ |- |

| | |2.1.2. Systems biology |√ |√ |

| |2.2. Research on the brain and related diseases, human development and ageing |√ |√ |

| | |2.2.1. Brain and brain-related diseases |√ |√ |

| | |2.2.2. Human development and ageing |√ |- |

| |2.3. Translational research in major infectious diseases: to confront major threats to public health |√ |√ |

| | |2.3.1 Anti-microbial drug resistance including fungal pathogens |- |√ |

| | |2.3.2. HIV/AIDS, malaria and tuberculosis |√ |√ |

| | |2.3.3. Potentially new and re-emerging epidemics |√ |√ |

| | |2.3.4. Neglected infectious diseases |- |√ |

| |2.4. Translational research in other major diseases |√ |√ |

| | |2.4.1. Cancer |√ |√ |

| | |2.4.2. Cardiovascular disease |√ |√ |

| | |2.4.3. Diabetes and obesity |√ |√ |

| | |2.4.4. Rare diseases |√ |- |

| | |2.4.5. Other chronic diseases |√ |√ |

|3. OPTIMISING THE DELIVERY OF HEALTH CARE TO EUROPEAN CITIZENS |- |√ |

| |3.1. Translating the results of clinical research outcome into clinical practice including better use of |- |√ |

| |medicines, and appropriate use of behavioural and organisational interventions and new health therapies and | | |

| |technologies | | |

| |3.2. Quality, efficiency and solidarity of health care systems including transitional health systems |- |√ |

| |3.3. Enhanced health promotion and disease prevention |- |√ |

| |3.4. Horizontal coordination and support actions across ”optimising the delivery of health care to European |- |√ |

| |citizens” | | |

|4. OTHER ACTIONS ACROSS THE HEALTH THEME |√ |√ |

| |4.1. Coordination and support actions across the Theme |√ |√ |

| |4.2. Responding to EU policy needs |√ |√ |

|PPF_FP7_T1.4 Description of previous and present experience in International Cooperation |

|(max. 10 lines) |

| |

|CIC&TS has signed protocols, or already made steps for creating such protocols, with the universities of: Estremadura and Barcelona (Spain), |

|Federal de Paraiba Estadual do Sudoeste da Bahia and Federal do Rio Grande do Norte (Brazil), Pildusky Academy (Poland), Zinmann College of |

|Sports Medicine, Wingate Institute (Israel), Verona (Italy), Odense (Denmark), the Sport Hogh Schule of Koln (BRD). Further contacts will be |

|undertaken with the Vrije Universiteit Brussel (Belgium) in order to create a Master Degree in Medical Geriatrics. This last element will be |

|developed if we receive the agreement of the Portuguese Medical Doctors Order. |

|PPF_FP7_T1.4.1 Participation in EU Framework Programme (FP) projects |

| | |

| |YES NO |

|If yes: |

|Project 1 Title / Acronym (Activities| |

|performed) | |

|Project 2 Title / Acronym (Activities| |

|performed) | |

| | |

|PPF_FP7_T1.5. Topics of interest in the Health Theme Work Programme (WP) |

|Call reference |FP7-HEALTH-2007-B |

|WP Topic |HEALTH-2007-2.4.5-11: Translational research aiming for a treatment of urinary incontinence |

| |HEALTH 2007 3.1-1: Implementation of research into health care practice |

| |HEALTH-2007-3.1-6: Continuity of clinical care. |

| |HEALTH 2007 3.1-7: Patient self-management of chronic disease |

| |HEALTH 2007 3.2-4: Health care human resource planning in nursing |

|Project Type | Large Collaborative Project Small or Medium Collaborative Project |

| |Network of Excellence Coordination and Support Action OTH ________________ |

| |

|PPF_FP7_T1.5.1 Expertise/ Commitment offered |

|Keywords specifying the |Aging; Elderly; Health condition; Healthcare; End of life; Aging and familiar context; Aging at home; |

|expertise: |Communication and information technologies; Evidence based practice; Skeletal tissues biology; Biomechanics |

| |and mechanobiology of the musculoskeletal system; Biomaterials; Orthopaedics implants; Functional morphology;|

| |Body and Physical Condition; Physical activity; Rehabilitation; Well-being. |

|Description of the expertise: |Techniques and facilities for the study of the musculoskeletal system and skeletal tissues biology. |

| |Techniques and equipment for: monitoring body and physical condition, performance, biological and |

| |physiological parameters; human movement and analysis. Study of the life style, health condition, physical |

| |and mental functionality of the elderly population. Development of middle-range theories about care |

| |modalities for people reaching the life’s end. Understand the relationship between the process of aging and |

| |familiar context. Understand aging at home with health cares. Development of communication and information |

| |technologies to the elderly population. Healthcare evidence based practice for elderly population. |

|Role/Commitment offered |Technology development Research Demonstration |

| |Training Dissemination Other |

|PPF_FP7_T1.6 Interests on other Themes of the 7FP Specific Programme “Cooperation” |

| | No YES |

|If yes: |

| | |

| |Food, Agriculture, Fisheries and Biotechnology |

| |Information and Communication Technologies |

| |Nanosciences, Nanotechnologies, Materials and new Production Technologies |

| |Energy |

| |Environment (including Climate Change”) |

| |Transport (Including Aeronautics) |

| |Socio-Economic Sciences and the Humanities |

| |Space |

| |Security |

|PPF_FP7.T1_7 I agree with the publication of my/our data: |

| | NO YES |

|PPF_FP7.8 Short guidelines on filling this Profile Form |

|The present form aims to help the researchers in disseminating their activities and interests as potential partners within the Health Theme |

|of the FP7 by assisting the process of partner search. |

|PPF_FP7.1 |The fields should be filled in order to allow the identification as a partner proponent and further |

| |contact by possible coordinators or other entities. |

|PPF_FP7.2 |A short description on the research team will allow the acknowledgement of the past and present |

| |activities. |

|PPF_FP7.3 |The activities and areas of interest in the “Health” calls for 2007 should be indicated. Note that not |

| |all the areas or activities are open for submission of proposals in the 2007 Health Work Programme (WP).|

|PPF_FP7.4 |Description of previous and present experience in International Cooperation (e.g. projects and partners |

| |involved). |

|PPF_FP7.5 |If the interest of the organization regards several topics under the same area, or different areas, |

| |additional lines can be introduced in order to cover all the information considered relevant. |

|PPF_FP7.6 |Information on activities and interest on areas of other Themes allows the identification of potential |

| |synergies – multidisciplinary projects/approaches. |

| PPF_FP7.7 |In order to best fulfil the goals intended, this form should be circulated to the international |

| |community of National Contact Points, and also among potentially interested parties. Note that also the |

| |online publication of the present information could be of great help in the process of consortium search|

| |for a submission of a proposal. |

|Please fill in the Partner Profile Form (PPF) and return it to: |

|NCP for “Health” Theme |Joana Camilo |

|Organisation |GRICES - Office for International Relations in Science and Higher Education Portuguese Ministry |

| |for Science, Technology and Higher Education |

|Tel. |(+351) 21 782 83 09 |

|E-mail |joana.camilo@grices.mctes.pt |

|ACRONYM |STRESS-PEDS (indicative…) |

|TITLE |Biobehavioral consequences of traumatic stress in childhood-adolescence: direct and transgenerational |

| |effects of stressful life events on mental health, growth and development. |

|TOPIC |-HEALTH-2007-2.2.1-10: Childhood and adolescent mental disorders. |

|Deadline |18 September 2007 – Tuesday 17:00 CET |

|MAIN HYPOTHESIS AND AIM: |To investigate the impact of traumatic stress in the development of mental disorders in |

| |childhood-adolescence. Diagnostic and therapeutic strategies and prevention of trauma-related mental |

| |disorders can be developed, based on the screening and assessment of behavioral, social, genetic and |

| |biological characteristics in children and adolescents (indicative …subject to change) |

|Call |- HEALTH-2007-2.2.1-10: Childhood and adolescent mental disorders. The research should be aimed at |

| |investigating paediatric mental disorders that have a high prevalence incountries of Central and Eastern |

| |Europe. The projects should use population genetics/genomics approaches and include |

| |bioinformatics/biostatistics to increase knowledge of the patterns of disease prevalence and develop |

| |possible diagnostic and therapeutic strategies as well as address prevention. Specific International |

| |Cooperation Action. Target regions: Eastern Europe and Central Asia and Western Balkans. Funding scheme: |

| |Collaborative projects (Small or medium-scale focused research projects). |

Work Package LIST

WP1. Management and Coordination

WP2. Good Clinical Practice, Quality Assurance and Harmonization

WP3. Data Management

WP4. Selection, evaluation, and adaptation of screening tools

WP5. Selection, dissemination and exploitation of results

WP6. School –based pediatric and adult behavioural screening and salivary

sampling

WP7. School -based evaluations: anthropometric, maturation and nutritional assessment, medical and developmental history

WP8. Child behavioural evaluations: clinical diagnosis, blood

sampling

WP9. Adult behavioural evaluations: clinical diagnosis, blood

sampling

WP10. Training of clinicians in therapeutic strategies

WP11. Interventions: adult/child trauma focused psychotherapy and follow-up

evaluations

WP12. Hormonal and biochemical analysis

WP13. Genetic and genomic analysis

WP14. MRS spectroscopy

WP15. Bioinformatics and Biostatistics of collected data

STRESS-PEDS Summary

INTRODUCTION

Mental health in childhood-adolescence: Almost 21% of children and adolescents have a mental disorder that can be diagnosed and 11% have significant impairment, while 70% of children with mental health problems do not receive special mental health services. Furthermore, children from low socioeconomic status having experienced a variety of stressors are more likely to need mental health care (Semansky, 2003). Early detection of not only developmental delays but also social-emotional and/or behavioural problems in childhood and adolescence is crucial. Indeed, the American Academy of Pediatrics (2001) recommended routine screening by pediatricians to enhance efforts to identify early social-emotional and behavioural problems. Such problems left untreated may affect learning and school performance, as well as relationships and social interactions, self–esteem and almost every aspect of the every-day life (Stanley, 2006).

The role of traumatic life events: There is also growing evidence of the mental health impact of all types of trauma. The exposure of large population groups, mostly having no previous mental health problems, in traumatic life events, such as natural disasters, war or violence, and the subsequent development -in a significant proportion of the population-of a variety of psychiatric symptoms and disorders represent a serious health problem. Evidence from a variety of mass traumatic life events shows that a significant proportion of the exposed population develops different mental disorders. Children, as well as the elderly, the disabled and those exposed to physical injuries represent the most vulnerable groups. The nature, severity and chronicity of the trauma may influence differentially the development and prevalence of subsequent mental disorders. Posttraumatic Stress Disorder (PTSD) is the most common trauma-related disorder, but one should also consider a variety of syndromes and disorders in addition to PTSD, like acute stress disorder (ASD), generalised anxiety, depression, substance abuse disorders, that can develop alone or comorbidly with PTSD. A better understanding of pathophysiology, vulnerability, resilience and recovery of posttraumatic symptomatology in children and adolescents, as well as effectiveness of interventions are essential in mental health care (Murthy, 2007).

PTSD and comorbidities in childhood-adolescence

Definition: Posttraumatic stress disorder (PTSD) describes a syndrome of distress that develops after exposure to events or circumstances that involved actual death or injury or a threat to the physical integrity of the individual or others and that evoked intense fear, helplessness, or horror. PTSD emerged as a clinical diagnosis in 1980 and it is classified as an anxiety disorder, based on the (DSM-IV). Symptoms include: 1) Re-experience of the initial trauma via intrusive memories and/or dreams about the event, feeling as if the trauma was continuing to occur, and intense distress on exposure to cues that recall the event. In young children, repetitive play or trauma specific re-enactment may occur in which themes or aspects of the trauma are expressed. 2) Avoidance of stimuli associated with the trauma and numbing of overall responsiveness. 3) Symptoms of excessive arousal, including insomnia, angry outbursts, hypervigilance, exaggerated startle response, and difficulty concentrating. PTSD lasts at least four weeks, as opposed to Acute Stress Disorder that begins within one month of the event and lasts from two days to four weeks (American Psychiatric Association).

Epidemiology: Children are more vulnerable to trauma than adults. Children and adolescents are about 1.5 times more likely to be diagnosed with PTSD when traumatized than adult trauma victims (Children of Trauma, 1998) In community samples of adolescents, a life- time prevalence of 5-10% was reported, while below age 10, PTSD prevalence was not adequately registered. Traumatic events or severe stressors have been recognized most often in children in cases of natural disasters, war, sexual or physical abuse and accidents (Dyregrov and Yule)

Comorbidities: PTSD is often comorbid by other clinical conditions, such as major depressive disorder (MDD) and generalized anxiety disorder (GAD) (Kar and Bastia, 2006) as well as a number of psychopathological manifestations such as somatic complains, depressive symptoms or symptoms of dissociation (Ruchkin, 2005). Depression seems to be the most common comorbid diagnosis of PTSD, being reported in around one third of the PTSD population in one study in adolescents while GAD was prevalent in 27%. Overlap of all three diagnoses may occur in a percentage of 14% (Kar and Bastia, 2006).

Biology of PTSD and associated disorders post-trauma

The hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS) are involved in the pathophysiology of PTSD. Neuroendocrine studies in adults with PTSD have demonstrated altered HPA axis activity, as evidenced by elevated basal cerebrospinal fluid (CSF) CRH concentrations (Baker et al., 1999) and seemingly contradictory results from peripheral measurements (Yehuda, 2001), showing low 24h excretion of urinary free cortisol in the majority of studies (Pitman and Orr, 1990; Yehuda et al., 1991; Yehuda et al., 1995; Yehuda, 2001), low or normal plasma cortisol levels (Boscarino, 1996; Yehuda, 2001) or even high cortisol levels (Lemieux and Coe, 1995; Maes et al., 1998). The direction of HPA activity, as evidenced by peripheral cortisol measures, may depend on age, gender, type and chronicity of stressor, co-morbid depression or other psychopathology, alcohol abuse and time since the traumatic experience. On the other hand, biomarkers of sympathetic nervous system activity are more consistent, showing in the majority of studies increased 24h urinary catecholamine excretion in PTSD patients compared to control subjects (Pitman and Orr, 1990; Yehuda et al., 1992; Southwick et al., 1999).

While the concepts of stress adaptation have been developed with reference to adults, the same principles also generally apply to children and adolescents. Endocrine systems, which are crucial for growth and puberty, including the gonadal, growth hormone and thyroid axes, are influenced by the HPA axis. Chronic changes in these systems during critical periods of development could have irreversible effects on maturation (Charmandari, 2003). In addition, it has been hypothesized that childhood trauma may alter CNS development: early severe stress results in elevated levels of glucocorticoids affecting specific, vulnerable brain areas (Teicher, 2002). Studies in children post trauma have shown increased SNS activity, as in adults, however, cortisol levels associated with this disorder have been reported high, normal or low (De Bellis et al., 1994; Goenjian et al., 1996; Ciccheti and Rogosch, 2001; De Bellis and Thomas, 2003; Pervanidou et al., 2007a). The majority of these studies examined hormone concentrations in already developed chronic PTSD.

Recent research has also focused on proinflammatory cytokines, such as interleukin (IL)-6, as indicators of the inflammatory response to physical and emotional stress and disruption of the HPA axis (Chrousos, 1995). Immune system functioning has been investigated in adults with PTSD and the majority of the studies have reported increased levels of circulating or CSF pro-inflammatory cytokines (Maes et al.,1999; Baker et al., 2001; Rohleder et al., 2004). Elevated IL-6 concentrations are found to be predictive of later PTSD development in children and adolescents after motor-vehicle accidents (Pervanidou et al., 2007b).

Transgenerational effects of trauma, paternal PTSD and fetal programming of the HPA axis and PTSD vulnerability

Parental PTSD is a significant risk factor for PTSD as evidenced by a greater prevalence of PTSD, but no trauma exposure in adult offspring of Holocaust survivors with PTSD (Yehuda). The extent to which any risk factor for PTSD is associated with parental exposure, including prenatal factors, is unknown. Transgenerational effects of trauma have been often attributed to nongenetic postnatal influences, such as traumatization of the offspring by the parents’s communication of their trauma to the child or other consequences of the parental symptoms, such as emotional/behavioral disorders leading to poor parenting (Yehuda, 1998). Other potential hypothesized mechanisms may be related to early social regulation (Gunnar, 2002), underlying genetic susceptibility (Bartels, 2003) or in utero glucocorticoid programming (Seckl 2004).

Genetics of PTSD

Although lifetime prevalence of exposure to traumatic events is between 40% and 90% in the general population, the overall lifetime prevalence of PTSD is estimated at 7-12% (Kessler 1995;Breslau 2001). PTSD is a complex and multifactorial disorder and, as in most other mental disorders, the genetic part may be viewed as polygenic: different genes interact or play an additional role in the onset of the disorder. Candidate genes that have been investigated in PTSD are the serotonin transporter (5-HTT), the dopamine transporter (DAT), the glucocoticoid receptor (GR), the GABA (A) receptor, the apolipoprotein E (APOE), brain-derived neurotrofic factor (BDNF) and neuropeptide Y (NPY). PTSD is highly comorbid with Major Depression (MA), as well as with other anxiety disorders (Kessler 1995). MD increases the risk of PTSD and other anxiety disorders and vice versa, while the associations between PTSD-MD-anxiety disorder may also be explained by a common genetic vulnerability.

Neuroimaging in PTSD

During the last decade, a number of studies have implicated various brain regions in PTSD, including portions of the frontal lobe, the amygdalae and the hippocampus (Villarreal and King, 2001). Several animal studies (Sapolsky, 1996) have shown hippocampal atrophy due to extreme stress, while clinical studies using magnetic resonance imaging (MRI) in PTSD subjects have shown smaller hippocampal volumes than in matched controls. Similar finding have been obtained in chronically maltreated children without the clinical diagnosis of PTSD (De Bellis). Studies using proton magnetic resonance spectroscopy (1H-MRS) have also revealed abnormalities in hippocampal biochemistry in PTSD subjects, commonly showing lower levels of hippocampal N-acetyl-aspartate (NAA), an excitatory neurotransmitter associated with neuronal integrity (Villarreal 2002).

OBJECTIVES

Through our study, we will shed light on the importance of traumatic life events and multiple stressors in the development of mental health disorders in childhood and adolescence. Investigation includes: the impact of trauma or chronic stress on growth, development and behaviour and the role of genetic vulnerability and/or parental-child interaction (transgenerational effects of trauma) in the development of the above disorders, including prenatal-perinatal influences such as prenatal stressors, and birth weight. In addition to genetic background, the biological component of PTSD and other disorders will be evaluated in detail with the baseline –and after the stress testing- neuroendoctine profiles.

The analyses of hormones and neurotransmitters, glucose, lipid metabolism, measurements of circulating insulin and other hormones and adipo-cytokines, and the evaluation of gene polymorphisms, will allow a better understanding of the relation of traumatic life events, psychopathology and growth and metabolic profile in children and adolescents.

The understanding of the epidemiology, biology and genetic basis of trauma-related disorders will lead to the development of new diagnostic and therapeutic strategies.

CBTs vs usual psychiatric care will be evaluated with the purpose of developing new therapeutic strategies, while mental health screening in schools and the primary care setting is the expected prevention- goal of the project.

STUDY DESIGN

Studies in schools

We will study 5000 children and adolescents, aged 8 to 15 y from 5 different countries in Europe and Target Regions recruited from primary and secondary schools. All children will have a detailed personal and family medical and psychosocial history taken and a full physical examination (height, weight, blood pressure, heart rate, and Tanner staging). All children will be screened using the CBCL (Achenbach), a life events questionnaire and a screening questionnaire for PTSD.

Salivary sampling will be performed, including two (obtained at 8-9 am and 8-9 pm) samples for the measurement of free cortisol and an additional morning sample for genetic studies. The Achenbach Questionnaire for adults will also be used for both parents, while salivary samples will also be obtained for cortisol and genetic studies.

Studies in mental health clinics

Children and parents scoring above the cut-off limits in the above mentioned questionnaires will be evaluated further by a board–certified child psychiatrist and adult psychiatrist, respectively. Clinical diagnoses will be made based on the ICD-10 (and/or the DSM-IV).

Children and parents diagnosed with PTSD and/or anxiety/depression with underlying trauma will be evaluated further. We estimate to study about 50-100 children and/or their parents per clinic in up to 5 centers. Cognitive-Behavioral Therapies, or the usual psychiatric care, will be offered to children suffering from PTSD and trauma related disorders, as well as to parents with psychopathology, independently of their children’s diagnosis. A morning fasting blood sample will be obtained for the measurement of plasma catecholamines, serum cortisol, IL-6 and other cytokines, as well as glucose/insulin and lipid profile. Measurements will be repeated after the end of the intervention sessions and six months later. Stress testing (cortisol responses in the Trier Stress Test) and neuroimaging will be optionally performed in selected children and parents.

All blood and salivary samples, as well as salivary samples for genomic studies will be analysed together in the same central laboratory.

Facilitating Centrally–Acting Locally: Interactive learning and change strategies to increase quality and efficiency in health care and nursing work.

Research director: Jaffar Kavian-Lanjani, PhD, Associate professor

Contact details:

Gasverksgatan 12, 46234 Vanersborg, Sweden

Tel: (+46) 70 6290552

Fax: (+46) 521 66567

Email: Jaffar.lanjani@

Abstract: The aim of the project “Facilitating Centrally – Acting Locally (FC-AL)” is to achieve knowledge about what is needed at the central level in order to enable qualitative and effective HCN-work at local workplaces and about what is needed at the local level in order to effectively transform quality assured knowledge into practical know-how in daily practise, while simultaneously assuring health and good working conditions of health care personnel.

We want to find driving/resistance forces, possibilities/hindrances in HCN work by carrying out two sub-projects, studying workplaces with different activity: (1) the integrated care chain of Stroke patients; (2) the integrated care chain of children and juveniles with psychiatric disorders. The learning, driving/resisting forces and obstacles from the first sub-project will be applied in the second in order to achieve double-loop learning.

The R & D organisations involved in the FC-AL project are: Forum for “Work Integrated Learning” at University West (UW); “Management and Leadership of Healthcare and Nursing Practice”, division for Health Promotion at dept. of Nursing Health and Culture (UW); Fyrbodal’s R & D centre for Primary Care (R&D); and University Centre of Vänersborg (UCV). The HCN professionals organisation involved are: “Integrated Health Care Fyrbodal”, Seamless Care Fyrbodal; “Stroke Forum” – a county council/municipal collaboration organisation for care of stroke patients; a specialist clinic at Norra Älvsborg Hospital regarding Emergency Care of stroke patients including investigation and rehabilitation; ward #12 at Uddevalla Hospital that functions as specialist clinic for stroke patients and also as educational centre for HCN staff; the organisation for investigation, care and rehabilitation of children and juveniles with psychiatric disorders within municipality of Vänersborg; the municipal social welfare organisation of Vänersborg; an advanced nursing home “Gläntans Sjukhem”, Vänersborg; a senior elderly home “Frändefors äldreboende”, a municipal rehabilitation and aid provider, Vänersborg; municipal patient relatives support organisation, Vänersborg; an occupational therapist unit, Vänersborg.

The FC-AL project builds on our knowledge and experiences from previous projects (best practice) at workplaces where participation and empowerment perspectives have been applied.

Previous studies show that staff within local units of HCN organisations have achieved improvements of their working conditions. Ongoing research is studying how to effectively unite the inter- and intraprofessional teamwork of HCN. The project has an interactive research approach to study the chain-of-patient care within the entire HCN system to ensure high quality patient care. The challenge is to implement change processes that can both contribute to development/improvement within single units and between the units, maintaining the current organisational structure. By FC-AL, organisational learning capability and change competence that provides tools for both inter and intraorganisational development will improve and develop the HCN activity. The aims of FC-AL can be achieved by applying 3 models used by us in earlier projects: (1) Work Integrated Interactive Learning (WIIL); developed by researcher/professional co-operation projects at public and private workplaces (2000-2006), aiming at strategies for employees and managers to manage work organisation problems; (2) Work Health Promotion (WHP); used in action oriented projects at county council and municipality level aiming at strategies for municipality top managers to improve teamwork for WHP(2001-2005) and prophylaxis at workplaces (2003-2004); (3) Future Workshop (FW); used in the nationwide project “Attractive Workplace”, based on development work carried out by personnel at 11 public health care centres (2002-2005). Through combination and implementation of these 3 models management and learning structures will be developed and the ability of local staff to actively apply new methods, models and processes at their workplace while producing high-quality, effective care and services will increase.

The combination of knowledge of the multidisciplinary research group, know-how of multiprofessional personnel from HCN with the “central-local” perspective not only facilitates identifying related inter- and intraorganisational problems, but also gives this research program a holistic approach complimentary to other research initiatives on development, effectiveness and high quality of HCN systems. Collaboratively studying different workplaces is a way to achieve quality-assured knowledge and to bridge the “gap” between research and the reality of daily work of professionals.

Our topics of interest for the next FP7 HEALTH Call are (according to ):

HEALTH-2007-3.2-2: Health systems and long term care of the elderly.

HEALTH-2007-3.2-3: Mobility of health professionals.

HEALTH-2007-3.4-3: Patient mobility and access to information.

HEALTH-2007-3.5-3: Health care intervention research – optimising hospital care.

4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME

HEALTH-2007-4.1-8: Promotion and facilitation of international cooperation in areas relevant to the objectives of this Theme.

Project #383

Project #383 - Medical University of Vienna - Austria

Date: 2007/08/31

Deadline: 2039/12/12

Contact

Organisation

Medical University of Vienna

Department

Department of Psychiatry and Psychotherapy

Contact person

Lanzenberger, Dr. Rupert

Email

rupert.lanzenberger@meduniwien.ac.at

Address

Waehringer Guertel 18-20

Postcode

1090

City

Vienna

Country

Austria

Telephone

+43 1 40400 3825

Fax

+43 1 40400 3825

Website

Familiar with the European Framework Programme? YES

PROJECT

Title: Mood Disorders European Study. Genetic vulnerability and environmental effects in pathogenesis and pharmacotherapy of mood disorders.

Acronym: MOODEST

Project type

Large-scale integrating collaborative project

Status

Planned for submission

Call references

Call 2nd

Priorities’ Main Research Areas

.

Workprogramme Topic (according to each priority workprogramme)

Project description

The scientific objectives of the project are

• The assessment of gene-environment interactions in the pathogenesis of mood disorders using new animal models, the genome wide association approach, endophentoypes and imaging genetics

• The identification of psychosocial and neurobiological surrogate markers for major depression and for prediction of antidepressant treatment outcome

• The assessment of functional and structural alterations in neuronal activation patterns and brain connectivity in depressed patients using neuroimaging

• The integration of molecular, preclinical and clinical data to a comprehensive pathophysiological perspective on mood disorders and antidepressant treatment outcome.

Keywords

.

Partners already involved

Project budget (for the running projects)

nc

Budget reserved for SMEs

nc

Research topics

• HEALTH-2007-2.2.1-8: From mood disorders to experimental models.

Profile of SME sought

Role

research

Country /region

Europe

Start of partnership

start-up phase

Expertise required

Bioinformatics; integration of large scale data (neuroimaging, genetics, biomarkers)

Profile #1795

Profile #1795 - JOANNEUM RESEARCH Forschungsges.mbH - Austria

Date: 2007/08/30

Deadline: 2010/01/31

Contact

Organisation

JOANNEUM RESEARCH Forschungsges.mbH

Department

Institute of Medical Technologies and Health Management

Contact person

Beck, MSc Peter

Email

peter.beck@joanneum.at

Address

Elisabethstraße 11a

Postcode

8010

City

Graz

Country

Austria

Telephone

+43(0)316 876 2136

Fax

+43(0)316 876 92136

Website

joanneum.at/msg

Organisation

Type:

Research Organisation & Universities

Is a Small and Medium Sized Enterprise (SME)? NO

Number of Employees

400

Description of research activity:

Our research activity spectrum reaches from organizational and public health concepts to software development for the healthcare system: The basis for providing optimum health services to as many people as possible is analysis, monitoring and improvement of the mechanisms underlying the complex, expensive health care systems. In close cooperation with local health authorities we work on the improvement of administrative and clinical processes in medical care, the optimisation of data management, patient-oriented care, and we perform cost analyses and project evaluations. We are currently involved in several real-life healthcare projects in Austria as well as in international research projects.

Current activities include:

- Evaluation of (integrated) health care projects

- Chronic disease management

- Patient education and patient empowerment

- Clinical documentation and quality management

- Evidence Based Medicine and clinical decision making and support

Former participation in an FP European project? YES

Project title / Acronym:

BIRO

Activities performed::

Clinical Review - Literature review to identify diabetes health indicators

Software design and development: Secure data transmission module

Design and specification: Data dictionary, reporting, system architecture

Research topics

• HEALTH-2007-3.1-2: Self-medication and patient safety.

• HEALTH-2007-3.1-4: Improving clinical decision making.

• HEALTH-2007-3.1-6: Continuity of clinical care.

• HEALTH-2007-3.1-7: Patient self-management of chronic disease.

• HEALTH-2007-3.2-1: Evaluation of disease management programmes.

Expertise/commitment offered

Keywords specifying the expertise:

chronic disease management, quality management, information systems, decision support, clinical decision making, information retrieval, workflow modelling, cost analysis, cost effectiveness, patient education, patient empowerment

Description of the expertise:

We have strong experience and research interest in the following domains:

- chronic disease management

- quality management in the care of chronically ill patients

- implementation of information systems in healthcare for administration and clinical care

- decision support and clinical decision making

- information retrieval

- workflow modelling

- patient education and patient empowerment

- cost analyses, cost-effectiveness, economic evaluation

Joanneum Research has provided the necessary know-how and manpower for setting up and running national competence centres as well as numerous large international projects including R&D activities on a European level, co-ordinating and participating in several IST projects in FP4, FP5 and FP6.

Commitment offered

Research,Technology

Expectations

Term commitment:

Long ( > 3 years)

Expected results for your organisation:

Our contributing in FP7 collaborative research projects aims at quality of care improvements for cronically ill patients.

We are interested in international networking to identify best practices for direct implemetation in wide-scale regional and national programs as well as scientific publication of the results.

CONTACT DETAILS

|Organisation |University of Kwazulu-Natal |

|Department |Pharmacy |

|Address |Private Bag X54001, Durban |

|City/area code |4000 |

|Country |South Africa |

|Contact person |Professor Sabiha Essack |

|e-mail |essacks@ukzn.ac.za |

|Phone |+2731 260 8048 |

|Fax |+2731 260 7872 |

PROJECT DETAILS

|Project type: | Large scale integrating | Networks of | CA or SSA |

| |collaborative project |Excellence | |

| | | | |

| |X Small or medium scale |SME | |

| |focussed research project | | |

|Planned to participate as: |X Partner | Coordinator |

|Call identifier : |HEALTH-2007-2.3.1-5 |

| | |

|Topic: |Evidence-Based Strategies for the Containment of Antibiotic Resistance |

|Your own research interests in|I am Y-rated by the NRF, have established the Antimicrobial Resistance Research Unit in the School of |

|relation to this project |Pharmacy and Pharmacology and have supervised/am currently supervising 3 PhD and 6 Masters students. I have|

| |secured several research grants for Essential National Health Research, from the World Health Organization, |

| |the Wellcome Trust, the Medical Research Council and the National Research Foundation investigating |

| |strategies for the prevention and containment of antibiotic resistance. |

| |I am the leader of the South African Chapter of the Alliance for the Prudent Use of Antibiotics and member of|

| |the National Antibiotic Surveillance Forum and the Federation of Infectious Diseases Societies of South |

| |Africa. |

| |Research: |

| |Strategies for Prevention and Containment based on Surveillance, Risk Factors, Clinical Significance, |

| |Infection Control, Pharmaco-economics and Drug Pharmacokinetics and Pharmacodynamics |

| |Molecular Biology/Genetics of Bacterial Resistance to Antibiotics (specifically beta-lactam antibiotics - |

| |penicillins, cephalosporins and related compounds) in Acinetobacter spp., Citrobacter spp., Enterobacter |

| |spp., Escherichia coli, Haemophilis influenzae, Klebsiella spp., Proteus mirabilis, Salmonella spp., |

| |Staphylococcus aureus and Streptococcus spp. |

| |Extended-Spectrum Beta-lactamase (ESBL)-Mediated Resistance |

| |Antibiotic Use and Resistance |

| |Nosocomiology and Infection Control |

| |Antibiotic Resistance Determinants in Agriculture |

|Expertise that you have to |I have hands-on expertise and experience in investigating the molecular biology and biochemistry of |

|offer in this call |antibiotic resistance by virtue of my Wellcome Trust Research Training Fellowship to St Bartholomew’s and the|

| |Royal London School of Medicine and Dentistry in the UK. I have been trained in epidemiology (Intensive |

| |Course in Epidemiology and Medical Statistics run by the London School of Hygiene and Tropical Medicine) and |

| |have undertaken epidemiological research. I have received several prestigious scholarships and bursaries |

| |from the Wellcome Trust, Medical Research Council (MRC) and National Research Foundation (NRF) and the |

| |University of Durban-Westville during the course of her Masters and PhD studies and my work has been |

| |published in several journals and has been presented at a number of national and international conferences. |

| | |

| | |

|Date |27 |08 |07 |Deadline |2007 |09 |09 |

|CONTACT |

|Organisation |Iuliu Hatieganu University of Medicine and |Department |Radiology |

| |Pharmacy | | |

|Contact person |Anca Butnaru |Male/female |Female |

|Address |Emil Isac str. No. 13 |Email |ancabutnaru@ |

| | | |cbotar@umfcluj.ro |

|Postcode |400023 |Fax |+40264597893 |

|City |Cluj-Napoca |Telephone |+40264595934 |

|Country |Romania |Website |umfcluj.ro |

Are you familiar with the European Framework Programme?

| YES |X NO |

PROJECT

|Ultrasound of cervical lymph nodes and cerebral MRI - | | | |

|correlation with CD4 lymphocytes level in HIV | | | |

|infected children | | | |

|Project type | Large Collaborative Project | Network of Excellence |X Small Collaborative | Other:       |

| | | |Project | |

|Status |X planned for submission | running EU project |

|Call references |Second call |HEALTH-2007-2.3.2-12 |

|Priorities’ Main Research |HIV/AIDS, malaria and tuberculosis |

|Areas | |

|Workprogramme Topic |HEALTH-2007-2.3.2-12 |

| | |

|Project description |The lymph nodes are the main localization for HIV virus. The pathogenesis of the cerebral damage in HIV |

| |infection is still not completely clear. Using gray scale, color, pulse and power Doppler, and elastography |

| |methods is possible to evaluate the lymph nodes structure, vascularizations and elasticity. The |

| |histopathological patterns of HIV-related limphadenopathy follow parallel the decline in CD4 lymphocytes. The|

| |HIV-related ultrasound findings are the expression of histopathological changes and correspond also with the |

| |decline in CD4 lymphocytes. Using lymph nodes ultrasound examination becomes possible to establish in the |

| |group of CD4 lymphocyte level (1, 2 or 3) in follow up period of treatment, without measuring the CD4 |

| |lymphocyte count. Imaging findings of CNS in HIV infection precede and accompany the cognitive abnormalities |

| |and/or neurological symptoms. Regular IRM investigation of CNS in HIV infected children, (without known risk |

| |effect) allow the possibility to underline the early cerebral involvement and development of HIV |

| |leukoencephalopathy. Associated lesion such as progressive multifocal leukoencephalopathy, HIV related |

| |vasculopathy and opportunistic infections can be differentiated using MRI methods, and the weight of each |

| |imaging finding in neurological symptoms may be estimated. We expect to demonstrate the imaging value in |

| |orientating and indicating the real time for usage of therapie. |

|Keywords |Lymphadenopathy, central nervous system, CD4, HIV, imaging, |

|Partners already involved |Department of Infectious Disease |

|Project budget (for the |      |Budget reserved for SMEs |      |

|running projects) | | | |

|Profile of Partner sought |

|Role | technology development |X research | training |

| |X dissemination | demonstration | other:       |

|Country /region |Eastern Europe, Central Asia |

|Start of partnership |X start-up phase | mid-term | end-phase |

|Expertise required |Ultrasound (including elastography), MRI, CD4 lymphocytes level |

De Autism in Fragile X: Microarray Identification of FMRP Associated Mrnas and Altered Profiles Related With Methylation Status of FMR1 Gene

Work Programme Topic: 2.2.1-10 Childhood and adolescent mental disorders (SICA)

Aim: A number of clinical features including epilepsy, MR, hypersensitivity to tactile stimuli, social deficits, and even loose stools have been hypothesized to be related to enhanced mGluR5 activity and LTD in FXS. This is important for clinicians to understand because these findings have direct therapeutic implications. Both mGluR5 antagonists and ampakines that stimulate the AMPA receptors are in investigational stages of development and they have potential to be specific treatments for FXS in the future. Both the genetic and the neural properties of FXS point out the importance of considering the network level, not just the level of individual genes or individual neurons. Although FXS is in one sense a single-gene disorder, it is more proximally the result of disruption in regulatory networks via the many genes whose transcripts FMRP binds, and probably in many cellular processes. This very complexity is what gives FXS the power to disrupt brain development. Similarly, as a single-gene disorder whose analysis illuminates networks of interacting genes and networks of interacting neurons, FXS opens for us a route to understanding the complexity of autistic development and a possibility of producing targeted therapies.

Recent reported data suggested that elevated FMR1 mRNA, but not CGG repeat size or reduced FMRP (as measured by immunocytochemistry), was significantly associated with increased autistic development such as the other psychological symptoms in Fragile X syndrome. In this project, it was aimed to draw a profile of mRNAs that are previously reported as selectively associated with FMRP-mRNP complexes to identify a subset of FMRP associated messages that play role in autism.

Partners are welcome from all EU, Eastern Europe, Western Balkans and Central Asia

- Experienced in applications of microoarray and molecular genetics.

OR

- Experienced in bioinformatics, population genetics, and microarray data analysis

OR

- Clinicians (pediatric neurologist, neurologist, pediatric psychiatrist or psychologist) experienced in clinical practices of mental retardation and autism developmental disorder in children with high patient circulation having these criteria.

Contact:

Prof. (Mrs) Ajlan TUKUN

Professor of Medical Genetics

Department of Medical Genetics

Ankara University Faculty of Medicine

06100 Ankara TURKEY

Please send e-mails

To: tukun@medicine.ankara.edu.tr

CC: ebruk@omega-.tr

CC: hakana@omega-.tr

|Date |2007 |8 |09 |Deadline |07 |9 |18 |

Below the Data of a partner who wants to a.) join a consortium b.) coordinate a project and searches for suitable partners or c.) the data of a Consortium which is in need of additional partners with certain expertise / equipment is given.

|CONTACT |

|Organisation |University Hospital Heidelberg |Department |Internal Medicine |

|Contact person |Prof. Katus, Dr. Hilbel, J Radeleff |Male/female |male |

|Address |Im Neuenheimer Feld |Email |Thomas.hilbel@med.uni-heidelberg.de |

|Postcode |D-69120 |Telephone |++4962215639780 |

|City |Heidelberg |Fax |++496221565516 |

|Country |German |Website |

| | | |e-Medizin-III-Kardiologie-Angiologie-und-Pn|

| | | |eumologie.3105.0.html |

G

|X YES | NO |

Are you familiar with the European Framework Programme?

| YES | NO |

Have you participated in a former European FP?

| |

If yes please indicate the project or activity:

|Project |

|Title European system of Diagnosis related groups |Acronym |

|(DRG) | |

|Project type | Large Collaborative Project |X Small or medium | Network of Excellence | Other: _____________ |

| | |Collaborative Project | | |

|Planned to participate as|X partner | coordinator |

|Call identifier |HEALTH-2007-3.2-8 |

|Workprogramme Topic you |Theme 1 X |Theme 2 |

|are interested in | | |

| |European system of Diagnosis related groups (DRG) |

|Your main research areas / |Diagnosis-related groups (DRG) and Diagnostic codes for cardio vascular diseases |

|Description of research | |

|activities | |

| |

|Expertise / Commitment offered: Diagnosis-related groups (DRG) and Diagnostic codes for cardio vascular diseases |

|Description of the |Diagnosis-related groups (DRG) and coding for cardio vascular diseases |

|know-how/expertise and | |

|equipment you can provide | |

| | |

| | |

|Keywords specifying your |Diagnosis-related groups (DRG), diagnostic codes, |

|expertise |medical classification, medical coding, cardio vascular diseases |

| |clinical medicine, medical practice, new and emerging technologies |

|Have you already identified | | | |

|Partners for projects you are |Yes |Have you already contacted other partners? |Yes |

|interested in? | | | |

| |X No | |X No |

If you want to coordinate / build a consortium or have already formed a consortium, you may need additional partners. To identify suitable partners please state what expertise / equipment is required:

|Profile of Partner(s) sought |

|Expected Commitment | technology development |X research | training |

| | dissemination | demonstration | other ______________ |

|Country /region |Europe |

|Expected expertise / know-how |European system of Diagnosis-related groups (DRG) |

|and equipment which the |Health Economics |

|partner should contribute to |Health Care Management |

|the project(s) |Health Care Service |

| |Health Insurance |

| |Health Systems and Policies |

|Data submission to |Public databases |X Yes |

| | |No |

| |NKS affiliated organisations in Europe and |X Yes |

| |third countries |No |

| |Consortia |X Yes |

| | |No |

Interested Consortia and Partners should directly get in touch with the contact person given on page one.

PLEASE FILL IN THE PARTNER SEARCH FORM AND FORWARD IT TO:

Rolf Stratmann

Nationale Kontaktstelle Lebenswissenschaften

Rolf.Stratmann@dlr.de

Topic of interest

Sulfation in Trypanosoma cruzi: Involvement of sulfated oligosaccharides in parasite infection and/or in the pathogenesis of Chagas disease.

The general project of our laboratory is focused on the biochemical, molecular and functional characterization of glycoconjugates from lower eukaryont hemoflagellate organisms of paramount importance for human health. In the last years, we have studied the post-translational modifications of T. cruzi glycoproteins. In particular, we have determined for the first time the presence of sulfated glycoproteins in Trypanosomatids and preliminary results showed that sulfate groups may be main targets for humoral immune responses to cruzipain, a major antigen of Trypanosoma cruzi, the causative agent of Trypanosomiasis Americana or Chagas disease

Contact data

Name: Dr. Vilma G. Duschak

Institution: Departamento de Investigación, Instituto Nacional de Parasitología “Dr Mario Fatala Chaben”, ANLIS-Malbrán, Ministerio de Salud, Buenos Aires, Argentina

Address: Av Paseo Colón 568, Buenos Aires (1063), Buenos Aires, Argentina

Phone: + 541143314010/19

Fax + 541143317142

Email vduschak@yahoo.es / vduschak@

Possible input to project

• Expertise

We have got wide experience in working with Trypanosomatids, culture, rupture protocols, subcellular fractionation and localization of enzymes, biochemistry of proteins, histones and proteases, protein purification protocols, biochemical work with protease and its inhibitors, MALDI-ToF-MS analysis, techniques on carbohydrate analysis, glycobiology of parasites, on post-translational modifications as well as immunization protocols.

• Equipment

The Instituto Nacional de Parasitología Dr Mario Fatala Chaben, ANLIS, Ministerio de Salud y Ambiente, Buenos Aires, Argentina counts with a spectrophotometer for kinetics enzymatic determinations, Elisa reader, cell counter and microscopes. Our laboratory is equipped with equipment for biochemical research (a Thermo-Savant Speed vac concentrator mixers, balances, a microspin centrifuge, power supply, all the equipment needed for SDS-PAGE as well as for electroblotting of proteins, gel drier, pHmeter, etc). All materials required for the development of molecular biology aspects are also available. In addition, the Organic Chemistry Department, from University of Buenos Aires, counts with an high pH anion exchange chromatograph equipped with a pulse amperometric detector (HPAEC-PAD) specially dedicated for carbohydrate analysis, a Fuji LAS1000 densitometer equipped with Image Gauge 3.122, software, (Fuji Film) and a fluorimeter, and we work in collaboration with members of the mentioned Department.

• Infrastructure

The Instituto Nacional de Parasitología Dr Mario Fatala Chaben, ANLIS, Ministerio de Salud y Ambiente, Buenos Aires, Argentina, center of Diagnostic and Research of Chagas disease, has got all the facilities for Trypanosoma cruzi cultures and to work with laboratory animals. There are culture rooms equipped with laminar fluxes, ovens, centrifuges, sonicators and balances. There are rooms with freezers, liquid nitrogen containers, lyophilizator, and ultracentrifuges. In the laboratory from the diagnostic department three serologic tests are performed to 20000 patients per year by trained personal. The Research department is equipped with a room for radioactive protocols. There are laboratories of molecular biology (DNA automatic sequencing, PFGE equipment, cyclers) and biochemistry of proteins. In addition, I am member from CEQUIBIEN consorsium for the use of an UV-MALDI-TOF-TOF mass spectrometry equipment.

Contacts to other scientists in the same field of research (regional, national, international)

-Dr Alicia S Couto, CHIDECAR, Facultad Cs Exactas y Naturales, UBA

-Dr Jose Kovensky, Laboratoire des Glucides, Universite Jules Verne, Amien, France.

Suggestions for possible cooperation partners in the same field of research

(not necessarily established contacts)

We have studied post-translational modifications of the major cysteine proteinase of Trypanosoma cruzi. We have performed mice immunization prior and after desulfation treatment with the aim to evaluate involvement of sulfated oligosaccharides, components of parasite glycoproteins as tools in the control of T. cruzi infection and/or in the pathogenesis of the disease.

1) We propose interaction with experts in immunology, pathology or other fields to collaborate in our project

2) we are opened to consider interaction with other groups that require our collaboration in their works.

Other remarks

The cloning of the sulfotransferase (s) is also planned and a collaboration can be evaluated. All the studies can be further extended to chagasic patients.

Topic of interest

HEALTH2007-3.5-2 Universal and equitable access to health care and health financing

Contact data

Name Prof. Adolfo Rubinstein MD MSc PhD

Institution, Instituto de Efectividad Clínica y Sanitaria (IECS)

Address Viamonte 2146 , 3rd floor, C1056ABH Buenos Aires, Argentina

Phone +54-11-49534058

Fax +54-11-49534058

Email adolfo.rubinstein@.ar

Possible input to project

• Expertise

IECS is an independent, non-profit organization and leading health research institution in Latin America, devoted to research, education and technical cooperation, aiming at improving the efficiency, equity, quality and sustainability of health care systems and policies.

• Equipment

Our institute has a large facility with appropriate space to accommodate all the professional and administrative staff, including a conference room for 50 people. Other resources for research include a librarian, computer support staff, research assistants, programmers, secretarial and administrative staff and audio-visual equipment. Its facilities have WI-FI internet and are equipped with 30 IBM-compatible personal computers with LAN and WAN network; communication via electronic mail is routine.

• Infrastructure

IECS is composed of 12 full-time and 15 part-time investigators who are professionals from medical and social sciences, 4 research fellows and 7 administrative personnel for accountability, clerical work and project management. Its professional staff is integrated by clinical and health service epidemiologists, statisticians, health economists and social scientists.

Contacts to other scientists in the same field of research (regional, national, international)

-LATINCLEN (Inclentrust) Network in Brazil, Bolivia, Chile, Colombia, Mexico, Peru and Spain

-Cochrane network

Suggestions for possible cooperation partners in the same field of research

-----------------------

[1] Organization activity type (fill all that apply): HES - Higher Education (i. e. organisations only or mainly established for higher education/training, e. g. universities, colleges); IND - Industry (i. e. industrial organisations private and public, both manufacturing and industrial services such as industrial software, design, control, repair, maintenance); REC – Research organization (i. e. "research organisation" means a legal entity established as a non-profit organisation which carries out research or technological development as one of its main objectives); OTH – Others; N/A – Undefined.

-----------------------

Partner Search Form: South Africa

The data given will not be subjected to any technical pre-selection or control in regard to the quality or potential of the inquiry/requester.

Expression of interest for

cooperation

elan2life

internationalisin’ research

Expression of interest for

cooperation

elan2life

internationalisin’ research

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download